1.Multi-facet expressions of adenylate cyclase isoforms in B16-F10 melanoma cells differentiated by forskolin treatment.
Du Hyong CHO ; Chang Dae BAE ; Yong Sung JUHNN
Experimental & Molecular Medicine 2000;32(4):235-242
The terminal differentiation of malignant melanoma cells is known to be induced by activating cAMP signaling pathway with alpha-MSH or cAMP analogues. However, sustained activation of cAMP signaling system that induces the differentiation of melanoma cells, also induces the desensitization of the pathway at the receptor level. Nevertheless, the adaptation of adenylate cyclase (AC) expression by sustained activation of cAMP signaling system has not been clearly understood. This study was performed to examine whether the sustained activation of cAMP system induce changes in the expression AC isoforms as an adaptation mechanism. Treatment of B16/F10 murine melanoma cells with 100 mM forskolin for 6 days resulted in differentiation, melanin accumulation and increased expression of tyrosine hydroxylase mRNA. In the forskolin-treated melanoma cells, change in expression of various AC isoform at the transcription level was detected by reverse-transcription polymerase chain reaction (RT-PCR). Expression of AC isoform mRNA: ACI, III, VI, VII, and IX increased to the level of 196-392% of the control whereas the level of ACII was decreased by 30%. The cAMP concentration was increased both in basal and alpha-MSH stimulated cells, but the AC activity was decreased in the forskolin treated cells. Thus, these results suggest that sustained activation of cAMP system induces differential expression of AC isoforms, which results in increase of cAMP accumulation.
Adenylate Cyclase/*genetics
;
Animal
;
Cell Differentiation
;
Cyclic AMP/*metabolism
;
Forskolin/*pharmacology
;
Isoenzymes/genetics
;
Melanoma, Experimental/*enzymology/*pathology
;
Mice
;
Signal Transduction
2.Expression and regulation of pituitary adenylate cyclase-activating polypeptide mRNA in pregnant rat corpus luteum.
Wei ZHAO ; Dan-Ling CHENG ; Hui-Li ZHENG ; Hui ZHU ; Jiang NI
Chinese Journal of Applied Physiology 2010;26(3):313-317
OBJECTIVETo investigate the expression changes and regulation of pituitary adenylate cyclase-activating polypeptide (PACAP) mRNA in corpus luteum during pregnancy.
METHODSPregnant rats' ovaries were collected at different time points. The techniques of RT-PCR and in situ hybridization were used to observe expression changes of PACAP mRNA in rat ovaries during pregnancy. To further explore the regulation mechanism of PACAP mRNA expression in corpus luteum, luteal cells were cultured in vitro. Immature (25 - 28 days old) female Sprague-Dawley rats were injected subcutaneously with 50IU pregnant mare serum gonadotrophin (PMSG), and 25IU human chorionic gonadotrophin (hCG) 48 h later, to induce follicular development and luteum formation. On day 6 after hCG administration (the day of hCG administration was the first day), the rats were killed by guillotine and the ovarian luteal cells were collected. After incubation for 24 h, luteal cells were administration with various factors for 24 h. And then expression changes of PACAP mRNA in luteal cells after administration with different factors were detected by RT-PCR, and radioimmunoassay was used to analyze progesterone levels.
RESULTSWith the development of pregnancy, the expression of PACAP mRNA increased gradually, reached the peak at pregnancy 19 d, and then decreased. Compared with control group, platelet activating factor (PAF), forskolin and PMA could obviously stimulate PACAP mRNA expression in luteal cells which were cultured with corresponding factors for 24 h. At the same time, progesterone levels in culture media were also elevated.
CONCLUSIONPACAP, acting as a local ovary regulator, was closely related to the maintenance of medium-term and late pregnancy. PAF could directly stimulate PACAP mRNA expression in luteal cells, and protein kinase C (PKC) and protein kinase A (PKA) signal pathways could both participate in this process.
Animals ; Cells, Cultured ; Corpus Luteum ; metabolism ; Female ; Pituitary Adenylate Cyclase-Activating Polypeptide ; genetics ; metabolism ; Platelet Activating Factor ; metabolism ; Pregnancy ; RNA, Messenger ; genetics ; Rats ; Rats, Sprague-Dawley
4.Adaptation of cAMP signaling system in SH-SY5Y neuroblastoma cells following expression of a constitutively active stimulatory G protein alpha, Q227L Gsalpha.
Ik Soon JANG ; Yong Sung JUHNN
Experimental & Molecular Medicine 2001;33(1):37-45
Heterotrimeric GTP-binding proteins (G protein) are known to participate in the transduction of signals from ligand activated receptors to effector molecules to elicit cellular responses. Sustained activation of cAMP-G protein signaling system by agonist results in desensitization of the pathway at receptor levels, however it is not clear whether such receptor responses induce other changes in post-receptor signaling path that are associated with maintenance of AMP levels, i.e. cAMP-forming adenylate cyclase (AC), cAMP-degrading cyclic nucleotide phosphodiesterase (PDE) and cAMP-dependent protein kinase (PKA). Experiments were performed to determine the expression of AC, PDE, and PKA isoforms in SH-SY5Y neuroblastoma cells, in which cAMP system was activated by expressing a constitutively activated mutant of stimulatory G protein (Q227L Gsalpha). Expression of ACI mRNA was increased, but levels of ACVIII and ACIX mRNA were decreased. All of the 4 expressed isoforms of PDE (PDE1C, PDE2, PDE 4A, and PDE4B) were increased in mRNA expression; the levels of PKA RIalpha, RIbeta, and RIIbeta were increased moderately, however, those of RIIalpha and Calpha were increased remarkably. The activities of AC, PDE and PKA were also increased in the SH-SY5Y cells expressing Q227L Gsalpha. The similar changes in expression and activity of AC, PDE and PKA were observed in the SH-SY5Y cells treated with dbcAMP for 6 days. Consequently, it is concluded that the cAMP system adapts at the post-receptor level to a sustained activation of the system by differential expression of the isoforms of AC, PDE, and PKA in SH-SY5Y neuroblastoma. We also showed that an increase in cellular cAMP concentration might mediate the observed changes in the cAMP system.
3',5'-Cyclic-Nucleotide Phosphodiesterase/genetics/metabolism
;
Adenylate Cyclase/genetics/metabolism
;
Cyclic AMP/*metabolism
;
Cyclic AMP-Dependent Protein Kinases/genetics/metabolism
;
G-Protein, Stimulatory Gs/genetics/metabolism
;
Heterotrimeric GTP-Binding Proteins/genetics/*metabolism
;
Human
;
Isoenzymes
;
Isoproterenol/pharmacology
;
Mutation
;
Neuroblastoma/*metabolism
;
*Signal Transduction
;
Support, Non-U.S. Gov't
;
Tumor Cells, Cultured
5.SR144528 as Inverse Agonist of CB2 Cannabinoid Receptor.
Journal of Veterinary Science 2002;3(3):179-184
It is now well established that several G protein- coupled receptors can signal without agonist stimulation (constitutive receptors). Inverse agonists have been shown to inhibit the activity of such constitutive G protein-coupled receptor signaling. Agonist activation of the Gi/o-coupled peripheral cannabinoid receptor CB2 normally inhibits adenylyl cyclase type V and stimulates adenylyl cyclase type II. Using transfected COS cells, we show here that application of SR144528, an inverse agonist of CB2, leads to a reverse action (stimulation of adenylyl cyclase V and inhibition of adenylyl cyclase II). This inverse agonism of SR144528 is dependent on the temperature, as well as on the concentration of the cDNA of CB2 transfected. Pertussis toxin blocked the regulation of adenylyl cyclase activity by SR 144528.
Adenylate Cyclase/antagonists&inhibitors/genetics/metabolism
;
Animals
;
Binding, Competitive
;
Bornanes/metabolism/*pharmacology
;
COS Cells
;
Cannabinoids/metabolism
;
Cercopithecus aethiops
;
Isoenzymes/antagonists&inhibitors/genetics/metabolism
;
Pyrazoles/metabolism/*pharmacology
;
Rats
;
*Receptor, Cannabinoid, CB2
;
Receptors, Cannabinoid
;
Receptors, Drug/agonists/*antagonists&inhibitors/genetics/metabolism
;
Signal Transduction/drug effects/physiology
;
Transfection
6.Functional Role of Serine Residues of Transmembrane Dopamin VII in Signal Transduction of CB2 Cannabinoid Receptor.
Journal of Veterinary Science 2002;3(3):185-191
Using site-directed mutagenesis technique, I have replaced serine 285 and serine 292 with the alanine, and assessed the binding of agonist and signaling such as the inhibition of adenylyl cyclase activity.I have found that serine 292 has an important role in the signal transduction of cannabinoid agonists, HU-210 and CP55940, but not in that of aminoalkylindoles derivatives WIN55,212-2. All mutants express well in protein level determined by western blot using monoclonal antibody HA 11 as compared with the wild type receptor.Interestingly, binding affinity of S285A and S292A mutants with classical cannabinoid agonist HU-243 was somewhat decreased. In signaling assay, the inhibition of adenylyl cyclase by HU-210, CP55940 and WIN55, 212-2 is the same order in both wild type receptor and S285A mutant receptor. However, S292A have been shown that the inhibition curves of adenylyl cyclase activity moved to the right by HU-210 and CP55940, but those of adenylyl cyclase activity did not by aminoalkylindole WIN55,212-2, which is indicating that this residue is closely related to the binding site with HU-210 and CP55940. In addition, serine 292 might take more important role in CB2 receptor and G-protein signaling than serine 285.
Adenylate Cyclase/*metabolism
;
Animals
;
Binding, Competitive
;
Blotting, Western
;
COS Cells
;
Cannabinoids/metabolism
;
Cercopithecus aethiops
;
Cyclohexanols/metabolism
;
Excitatory Amino Acid Antagonists/metabolism
;
Mutagenesis, Site-Directed
;
Protein Conformation
;
Protein Structure, Tertiary
;
Receptors, Cannabinoid
;
Receptors, Drug/genetics/metabolism/*physiology
;
Serine/metabolism/*physiology
;
Signal Transduction/physiology
;
Tetrahydrocannabinol/*analogs&derivatives/metabolism
;
Transfection
7.Expression and characterization of VPAC2 in CHO cells.
Rong-Jie YU ; Yuan GAO ; Yun DAI ; Ngai-lik TAM ; Zhi-Hong ZENG ; Tian-Hong ZHOU ; An HONG
Chinese Journal of Biotechnology 2006;22(6):996-1001
VPAC2 is a co-receptor of pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) and mediates multiple bio-functions. In order to construct the CHO line expressing VPAC2 stably, pcDNA-VPAC2 was used to transfect CHO cells. The positive clones were selected by G418 and the clone VPAC2-CHO with high sensitivity to PACAP38 was picked out by its ability to promoting the concentration of cAMP. RT-PCR, Western blot and Immunofluorescenece assay were used to identify the express of VPACS. Binding competition with VPAC2 agonist and the bioactivity of mediating the ligand to promote the concentration of cAMP showed that VPAC2 was expressed effectively in VPAC2-CHO. The results of Scatchard analysis revealed that VAPC2-CHO expressed a receptor density of (1.1 +/- 0.2) pmol/mg protein, respectively, with Kd values of (0.55 +/- 0.10) nmol/L for PACAP38 used as a tracer. The construction of CHO cells expressing VPAC2 specially and functionally lays a foundation not only for the further research on the characters and functions of VPAC2 but also for the screening and characterization of novel agonists of antagonists for VPAC2.
Animals
;
Binding, Competitive
;
CHO Cells
;
Cell Membrane
;
drug effects
;
metabolism
;
Cricetinae
;
Cricetulus
;
Cyclic AMP
;
metabolism
;
Gene Expression
;
Genetic Vectors
;
genetics
;
Iodine Radioisotopes
;
chemistry
;
Pituitary Adenylate Cyclase-Activating Polypeptide
;
chemistry
;
metabolism
;
pharmacology
;
Receptors, Vasoactive Intestinal Peptide, Type II
;
agonists
;
antagonists & inhibitors
;
genetics
;
metabolism
;
Reverse Transcriptase Polymerase Chain Reaction
;
Transfection
8.Cross talk between P2 purinergic receptors modulates extracellular ATP-mediated interleukin-10 production in rat microglial cells.
Dong Reoyl SEO ; Soo Yoon KIM ; Kyung You KIM ; Hwan Goo LEE ; Ju Hyun MOON ; Jae Souk LEE ; Se Hoon LEE ; Seung U KIM ; Yong Beom LEE
Experimental & Molecular Medicine 2008;40(1):19-26
Previously we demonstrated that ATP released from LPS-activated microglia induced IL-10 expression in a process involving P2 receptors, in an autocrine fashion. Therefore, in the present study we sought to determine which subtype of P2 receptor was responsible for the modulation of IL-10 expression in ATP-stimulated microglia. We found that the patterns of IL-10 production were dose-dependent (1, 10, 100, 1,000 micrometer) and bell-shaped. The concentrations of ATP, ATP-gammaS, ADP, and ADP-beta S that showed maximal IL-10 release were 100, 10, 100, and 100 micrometer respectively. The rank order of agonist potency for IL-10 production was 2'-3'-O-(4-benzoyl)-benzoyl ATP (BzATP) = dATP > 2-methylthio-ADP (2-meSADP). On the other hand, 2-methylthio-ATP (2-meSATP), alpha,beta-methylene ATP (alpha,beta-meATP), UTP, and UDP did not induce the release of IL-10 from microglia. Further, we obtained evidence of crosstalk between P2 receptors, in a situation where intracellular Ca2+ release and/or cAMP-activated PKA were the main contributors to extracellular ATP-(or ADP)-mediated IL-10 expression, and IL-10 production was down- regulated by either MRS2179 (a P2Y1 antagonist) or 5'-AMPS (a P2Y11 antagonist), indicating that both the P2Y1 and P2Y11 receptors are major receptors involved in IL-10 expression. In addition, we found that inhibition of IL-10 production by high concentrations of ATP-gammaS (100 micrometer) was restored by TNP-ATP (an antagonist of the P2X1, P2X3, and P2X4 receptors), and that IL-10 production by 2-meSADP was restored by 2meSAMP (a P2Y12 receptor antagonist) or pertusis toxin (PTX; a Gi protein inhibitor), indicating that the P2X1, P2X3, P2X4 receptor group, or the P2Y12 receptor, negatively modulate the P2Y11 receptor or the P2Y1 receptor, respectively.
Adenosine Diphosphate/analogs & derivatives/pharmacology
;
Adenosine Triphosphate/analogs & derivatives/*pharmacology
;
Adenylate Cyclase/antagonists & inhibitors
;
Animals
;
Calcium/metabolism
;
Chelating Agents/pharmacology
;
Cyclic AMP-Dependent Protein Kinases/antagonists & inhibitors
;
Enzyme Inhibitors/pharmacology
;
Extracellular Space/drug effects/*metabolism
;
Gene Expression Regulation/drug effects
;
Interleukin-10/*biosynthesis
;
Microglia/*drug effects/enzymology/*metabolism
;
RNA, Messenger/genetics/metabolism
;
Rats
;
Rats, Sprague-Dawley
;
Receptor Cross-Talk/*drug effects
;
Receptors, Purinergic P2/agonists/antagonists & inhibitors/genetics/*metabolism
;
Thionucleotides/pharmacology